Our Company

Guided by Deep
Scientific Expertise &
Driven by a Passion
to Deliver

We are focused on harnessing the power of the TGF-beta superfamily, the target-rich biology behind the body’s remarkable capacity for cellular growth and repair. Our insights and protein engineering capabilities enable us to design first- and best-in-class candidates for serious and rare diseases. Our lead product, luspatercept, is being evaluated in two global Phase 3 studies in partnership with Celgene to treat chronic anemia in MDS and beta-thalassemia. We are also advancing clinical programs for neuromuscular diseases.

Read More

A New Approach to Engaging the Body’s Ability to Rebuild and Repair

We Are Building a Rich Pipeline Based on Leadership in TGF-Beta Biology


Hematology

Luspatercept

Hematology

Luspatercept
PreclinicalPhase 1Phase 2Phase 3
 
Myelodysplastic Syndromes
Myelodysplastic
Syndromes
MEDALIST StudyMEDALIST Study
COMMANDS Study (Planned)COMMANDS Study
Long-Term Extension StudyLong-Term Ext St
Beta-Thalassemia
Beta-Thalassemia
BELIEVE StudyBELIEVE Study
Long-Term Extension StudyLong-Term Ext St
BEYOND Study (Planned)BEYOND Study
Myelofibrosis
Myelofibrosis
Ph 2 StudyPh 2


PreclinicalPhase 1Phase 2Phase 3
 
Myelofibrosis
Sotatercept
 
Myelofibrosis
Investigator-Sponsored StudyInvest-Sponsored St


 

Neuromuscular

ACE-083
PreclinicalPhase 1Phase 2Phase 3

Neuromuscular

ACE-083
FSH Muscular Dystrophy
FSH Muscular Dystrophy
Ph2 Study (Part 1)Ph2
Charcot-Marie-Tooth Disease
Charcot-Marie-Tooth Disease
Ph2 Study (Part 1)Ph 2

Acceleron

News